Clinical trial data readouts for DYNE-101 (DM1) and DYNE-251 (DMD) - efficacy, safety, and muscle tissue penetration metrics
FDA regulatory interactions including IND clearances, Fast Track designations, and breakthrough therapy designations for lead programs
Cash runway updates and financing events (equity raises, partnerships) given $300M+ cash burn through potential commercialization
Competitive developments in oligonucleotide delivery platforms and rival DMD/DM1 programs from Sarepta, PepGen, and others
low - Clinical-stage biotech operations are largely insulated from GDP fluctuations as R&D spending follows scientific timelines rather than economic cycles. Patient enrollment in rare disease trials is driven by medical need, not discretionary spending. However, severe recessions can impact venture capital availability and public market valuations for pre-revenue biotechs.
Rising interest rates create significant headwinds through multiple channels: (1) higher discount rates compress NPV of distant future cash flows, disproportionately impacting pre-revenue companies with 5-7 year commercialization timelines, (2) risk-free rate competition makes speculative biotech investments less attractive versus bonds, (3) increased cost of capital for future financing rounds. The company's $330M+ cash position provides near-term buffer, but eventual need for additional capital makes rate environment critical for dilution risk.
Clinical trial failure risk - Phase 2/3 trials for DYNE-101 and DYNE-251 may not demonstrate sufficient efficacy or acceptable safety profiles, resulting in program termination and significant value destruction
Regulatory approval uncertainty - FDA may require additional studies, reject applications, or impose restrictive labels limiting commercial potential even with positive trial data
Oligonucleotide delivery competition - rival platforms (exon-skipping, gene therapy, alternative conjugation technologies) may demonstrate superior efficacy or safety, obsoleting FORCE platform advantages
growth - Attracts high-risk tolerance biotech specialists and growth investors seeking asymmetric returns from clinical-stage rare disease programs. Binary outcome profile (clinical success vs failure) appeals to venture-style public market investors willing to underwrite 5-7 year commercialization timelines. Not suitable for income or value investors given zero revenue, negative cash flow, and high volatility. Institutional ownership likely concentrated among specialized healthcare funds.
No analyst coverage available for this stock.
Trend
+0.4% vs SMA 50 · +15.4% vs SMA 200
Momentum
Accumulation pattern present — more buying days than selling over the past 20 sessions. Volume conditions support gradual price improvement.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
DYN News
Unable to load news
About
Dyne Therapeutics, Inc. operates as a biotechnology company. The Company focuses on transforming the lives of people with serious diseases by developing muscle-targeted therapies. Dyne Therapeutics offers its services in the United States.
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
DYN◀ | $17.39 | +0.00% | $2.9B | — | — | — | 1500 |
| $68.56 | -3.59% | $13.3B | — | +12626.1% | -14525.8% | 1500 | |
| $513.72 | -0.71% | $11.8B | — | +43205.3% | -3008.0% | 1500 | |
| $87.60 | +0.60% | $11.5B | — | +3288.2% | -4239.0% | 1500 | |
| $183.72 | -1.59% | $10.7B | 29.2 | +1871.5% | 680.1% | 1500 | |
| $206.53 | -0.59% | $10.6B | — | +6554.5% | -2868.8% | 1500 | |
| $74.81 | +1.81% | $10.5B | 51.8 | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -0.58% | — | 40.5 | +398893.5% | -3996.9% | 1500 |